The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis

Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affect...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroimmunology Vol. 167; no. 1; pp. 131 - 137
Main Authors Lolli, Francesco, Mazzanti, Benedetta, Pazzagli, Marta, Peroni, Elisa, Alcaro, Maria Claudia, Sabatino, Giuseppina, Lanzillo, Roberta, Brescia Morra, Vincenzo, Santoro, Lucio, Gasperini, Claudio, Galgani, Stefania, D'Elios, Mario Milco, Zipoli, Valentina, Sotgiu, Stefano, Pugliatti, Maura, Rovero, Paolo, Chelli, Mario, Papini, Anna Maria
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.10.2005
Subjects
Adolescent
Adult
Aged
Analysis of Variance
Antibodies - blood
Antibodies - classification
Autoimmunity
B cell
Diagnosis
Enzyme-Linked Immunosorbent Assay - methods
Female
Flow Cytometry - methods
Glycopeptides - chemical synthesis
Glycosylated antigen
Humans
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - blood
Multiple Sclerosis - classification
Multiple Sclerosis - diagnosis
Multiple Sclerosis - immunology
Myelin autoantibodies
ROC Curve
Sensitivity and Specificity
Autoimmunity
B cell
Multiple sclerosis
Glycosylated antigen
Diagnosis
Myelin autoantibodies
Online AccessGet full text

Cover

More Information
Summary:Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs ( p < 0.001) or versus other autoimmune diseases (SLE or RA, p < 0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2005.05.016